Expert consensus established around flexible, individualized migraine treatment utilizing a modified Delphi panel

Author:

Graf Marlon1ORCID,Kim Edward2,Brewer Iris1,Hernandez Jennifer1,Chou Jacquelyn W.1,Cirillo Jessica2,Jensen Christopher2,Lipton Richard3

Affiliation:

1. PRECISIONheor Bethesda Maryland USA

2. Biohaven Pharmaceuticals, Inc New Haven Connecticut USA

3. Albert Einstein College of Medicine Bronx New York USA

Abstract

AbstractObjectiveTo characterize treatment decision‐making processes and formalize consensus regarding key factors headache specialists consider in treatment decisions for patients with migraine, considering novel therapies.BackgroundMigraine therapies have long been subject to binary classification, acute versus preventive, due to limitations of available drugs. The emergence of novel therapies that can be used more flexibly creates an opportunity to rethink this binary classification. To determine the role of these novel therapies in treatment, it is critical to understand whether existing guidelines reflect clinical practice and to establish consensus around factors driving management.MethodsA three‐round modified Delphi process was conducted with migraine clinical experts. Round 1 consisted of an online questionnaire; Round 2 involved an online discussion of aggregated Round 1 results; and Round 3 allowed participants to revise Round 1 responses, incorporating Round 2 insights. Questions elicited likelihood ratings (0 = highly unlikely to 100 = highly likely), rankings, and estimates on treatment decision‐making.ResultsNineteen experts completed three Delphi rounds. Experts strongly agreed on definitions for “acute” (median = 100, inter‐quartile range [IQR] = 5) and “preventive” treatment (median = 90, IQR = 15), but noted a need for treatment customization for patients (median = 100, IQR = 6). Experts noted certain aspects of guidelines may no longer apply based on established tolerability and efficacy of newer acute and preventive agents (median = 91, IQR = 17). Further, experts agreed on a treatment category referred to as “situational prevention” (or “short‐term prevention”) for patients with reliable and predictable migraine triggers (median = 100, IQR = 10) or time‐limited periods when headache avoidance is important (median = 100, IQR = 12).ConclusionsUsing the modified Delphi method, a panel of migraine experts identified the importance of customizing treatment for people with migraine and the utility of “situational prevention,” given the ability of new treatment options to meet this need and the potential to clinically identify patients and time periods when this approach would add value.

Publisher

Wiley

Subject

Neurology (clinical),Neurology

Cited by 4 articles. 订阅此论文施引文献 订阅此论文施引文献,注册后可以免费订阅5篇论文的施引文献,订阅后可以查看论文全部施引文献

1. Situational prevention: Pharmacotherapy during periods of increased risk for migraine attacks;Headache: The Journal of Head and Face Pain;2024-07

2. Migraine in women;Headache: The Journal of Head and Face Pain;2024-06-14

3. Approach to the Diagnosis and Treatment of Headache;Primary Care: Clinics in Office Practice;2024-06

4. Preventive Treatment of Migraine;CONTINUUM: Lifelong Learning in Neurology;2024-04

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线,采集、加工和组织学术论文而形成的新型学术文献查询和分析系统,可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容,当前同舟云学术共收录了国内外主流学术期刊6万余种,收集的期刊论文及会议论文总量共计约1.5亿篇,并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询!咨询电话:010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号  京ICP备18003416号-3